India tightens grip on GLP-1 supply chain amid misuse concerns, expands crackdown on unapproved drugs

India's drug regulator is increasing checks on weight loss drug sales. This action follows inspections of pharmacies and clinics nationwide. The goal is to prevent illegal sales of these specialized medicines. Authorities are also cracking down on unapproved drug combinations. Patient safety is the top priority as regulators enforce rules across the pharmaceutical supply chain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RS4iu8U
via IFTTT

Read More

GST refund stress: MedTech sector flags cash crunch, seeks relief

India's medical device sector is facing severe financial strain, prompting an urgent plea to the government for expedited GST refund processing. Delays in refunds from last year's rate reduction, coupled with rising input costs due to the West Asia conflict, have created significant working capital distress.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xhkNyF1
via IFTTT

Read More

India’s drug regulator flags 90 unapproved FDCs, directs states to take action

India's drug regulator has initiated a nationwide crackdown on unapproved fixed-dose combination drugs. At least 90 such medicines have been identified. States are directed to take immediate action against manufacturers, marketers, and distributors. This move follows lab testing data analysis. The Drugs Controller General of India emphasizes zero tolerance to protect public health and safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x7SGmTb
via IFTTT

Read More

Price alone won't push weight-loss, diabetes drug semaglutide sales: Doctors

Leading drugmakers including Sun Pharmaceuticals, Dr Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Eris Lifesciences, USV, Glenmark, and Torrent were among the first to roll out generic semaglutide on the first day of patent expiry of Novo Nordisk’s innovator molecule on Saturday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/my3X8YP
via IFTTT

Read More

India is well positioned to attract future investments, says Eli Lilly's Patrick Johnson

Faster ApprovalsFaster, predictable, and globally aligned clinical trial approvals are critical for India to attract high-value research and strengthen scientific capability and capacityPatrick JohnsonExecutive Vice President of Eli Lilly and Company and President of Lilly International

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SmdTnVf
via IFTTT

Read More

Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 Diabetes

Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to receive DCGI approval for this GLP-1 receptor agonist. Available in 2mg and 4mg strengths, the once-weekly subcutaneous injection demonstrated non-inferior efficacy and a comparable safety profile in Phase III studies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eMFf0PI
via IFTTT

Read More

Natco, Eris Life to launch slimming shots in both Vial and Pen formats

Natco Pharma and Eris Lifesciences are launching generic semaglutide weight-loss injections. The companies are introducing both vial and pen formats. This move aims to make the treatment more affordable. Vials will be available first, targeting a wider patient base. Pens are expected later for metropolitan markets. This strategy offers patients pricing flexibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wPXzTLW
via IFTTT

Read More